Meeting
2016 ASCO Annual Meeting
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
Authors
Claire Frances Friedman
Memorial Sloan Kettering Cancer Center, New York, NY
Claire Frances Friedman , Pedram Navid-Azarbaijani , Alexander Noor Shoushtari , Shonnette C. Campbell , Margaret K. Callahan , Parisa Momtaz , Nana A. Prempeh-Keteku , Michael Andrew Postow , Yelena Shames , Jedd D. Wolchok , Paul B. Chapman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02186249
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9519)
DOI
10.1200/JCO.2016.34.15_suppl.9519
Abstract #
9519
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
First Author: Sharon Hyo-Eun Nahm
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
First Author: RuiQui Chen
Poster
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
First Author: Paul Lorigan
Poster
2023 ASCO Annual Meeting
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
First Author: Anna Maloney